A carregar...
Tolvaptan, hyponatremia, and heart failure
Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion. Tolvaptan...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108793/ https://ncbi.nlm.nih.gov/pubmed/21694950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S7032 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|